

To give you the best possible experience, this site uses cookies. Continuing to use esgct.eu means you agree to our use of cookies. If you would like to learn more about the cookies we use please click here. [ACCEPT COOKIES](#)



<b>Tuesday 22 October 2019</b>	
16:30- 19:00	<p><b>2018 Opening session</b> <i>Chairs: Hildegard Büning, Fàtima Bosch, Angel Raya</i></p> <p><b>INV01: Andrea Ballabio</b> <i>Tigem, Naples</i> Title TBC</p> <p><b>INV02: Masaio Takahashi</b> <i>Riken, Kobe</i> Title TBC</p>
19:00- 20:00	<b>Welcome reception</b>
<b>Wednesday 23 October 2019</b>	

08:30-10:30	<p><b>Session 1a: Latest news from cardiovascular and pulmonary gene therapy</b>  <i>Chairs: Pilar Sepulveda, Uta Griesenbach</i></p> <p><b>INV03: Mauro Giacca</b>  <i>ICGEB, Trieste</i>  Title TBC</p> <p><b>INV04: Maria Blasco</b>  <i>CNIO, Madrid</i>  Title TBC</p> <p><b>INV05: Seppo Ylä Herttua</b>  <i>University of Eastern Finland, Kuopio</i>  Recent developments in cardiovascular gene therapy</p> <p>2 Oral presentations</p>	<p><b>Session 1b: Advancement in cancer</b>  <i>Chairs:</i>  <b>Sponsor: Molmed</b></p> <p><b>INV06: Cristina Fillat</b>  <i>Idibaps, Barcelona</i>  Title TBC</p> <p><b>INV07: Chiara Bonini</b>  <i>SR Tiget, Milan</i>  Title TBC</p> <p><b>INV08: Vincenzo Cerullo</b>  <i>University of Helsinki</i>  Title TBC</p> <p>2 Oral presentations</p>	<p><b>Session 1c: iPSC &amp; organoids, research and therapy developments</b>  <i>Chairs:</i></p> <p><b>INV09: Nico Lachmann</b>  <i>Hannover Medical School</i>  The „New Stem Cell“: macrophages for disease modeling and cell based therapies</p> <p><b>INV10: Nuria Montserrat</b>  <i>IBEC Barcelona</i>  Title TBCT</p> <p><b>INV11: Alfonso Martinez-Arias</b>  TBC</p> <p>2 Oral presentations</p>	<p><b>Session 1d: Viral vectors manufacturing</b>  <i>Chairs: Eduard Ayuso, Philippe Moullier</i>  <b>Sponsor: Oxford Biomedica</b></p> <p><b>INV12: Richard Snyder</b>  <i>Brammer Bio</i>  Viral vector manufacturing and testing</p> <p><b>INV13: Matthias Hebben</b>  <i>LogicBio</i>  Title TBC</p> <p><b>INV14: Hanna Lesch</b>  <i>FinVector, Kuopio</i>  Translational research of AAV expressing VEGF-B: large scale manufacturing process development, analytical development and pre-clinical studies in ischemic porcine model</p> <p><b>INV15: Amine Kamen</b>  <i>McGill University</i>  Process Intensification for Manufacturing of Viral Vectors for Cell and Gene Therapy</p>
10:30-11:00	<b>Coffee break</b>			

11:00-13:00	<p style="text-align: center;"><b>Plenary session 2: From Pre-clinical to clinical</b>  <i>Chairs: Juan Bueren,</i>  <b>Sponsor: Biopharma Excellence</b>  <b>INV12: Steve Brown</b>  <i>IMPC, Harwell</i></p> <p style="text-align: center;">The International Mouse Phenotyping Consortium (IMPC): Delivering a comprehensive catalogue of mammalian gene function and novel pre-clinical models</p> <p style="text-align: center;"><b>INV13: Fàtima Bosch</b>  <i>UAB, Barcelona</i>  Title TBC</p> <p style="text-align: center;"><b>INV14: Matthew Porteus</b>  <i>Stanford University, CA</i>  Title TBC</p> <p style="text-align: center;"><b>INV15: Luigi Naldini</b>  <i>SR Tiget, Milan</i>  Title TBC</p>
13:00-15:00	<p style="text-align: center;"><b>Lunch</b>  <b>Poster session I sponsored by Gilead</b></p>
15:00-17:00	<p style="text-align: center;"><b>Plenary session 3: Clinical trials</b>  <i>Chairs: TBC</i>  <b>Sponsor: RegenX</b>  <b>INV28: David Williams</b>  <i>Harvard Medical School</i>  Title TBC</p> <p style="text-align: center;"><b>INV29: Fulvio Mavilio</b>  <i>Audentes Therapeutics, San Francisco, CA</i>  Title TBC</p> <p style="text-align: center;"><b>INV30: Alberto Auricchio</b>  <i>TIGEM, Naples</i>  Gene therapy of mucopolysaccharidosis type VI</p> <p style="text-align: center;"><b>INV31: TBC</b>  <i>TBC</i>  Title TBC</p>
17:00-17:30	<p style="text-align: center;"><b>Coffee break</b></p>

17:30-19:30	<p><b>Session 2a: Skeletal, muscle &amp; bone gene and cell therapy</b>  <i>Chairs: Marinee Chuah, Ana Buj Bello</i>  <b>Sponsor: Myocure</b></p> <p><b>INV16: Thierry VandenDriessche</b>  <i>VUB, Brussels</i>            Title TBC</p> <p><b>INV17: Pura Muñoz</b>  <i>Universidad Pompeu Fabra, Barcelona</i>            Title TBC</p> <p><b>INV18: TBC</b></p> <p>2 Oral presentations</p>	<p><b>Session 2b: First in man</b>  <i>Chairs: TBC</i></p> <p><b>Sponsor: Orchard Therapeutics</b></p> <p><b>INV19: Adrian Thrasher</b>  <i>UCL, London</i>            Evolving haematopoietic stem cell gene therapy</p> <p><b>INV20: Alessandro Aiuti</b>  <i>SR Tiget, Milan</i>            Title TBC</p> <p><b>INV21: Don Kohn</b>  <i>UCLA, CA</i>            Title TBC</p> <p>2 Oral presentations</p>	<p><b>Session 2c: Next generation engineered T&amp;NK cells</b>  <i>Chairs: TBC</i></p> <p><b>INV22: John Maher</b>  <i>UCL, London</i>            Title TBC</p> <p><b>INV23: Pablo Menendez</b>  <i>Josep Carrera Research Center, Barcelona</i>            Title TBC</p> <p><b>INV24: Concetta Quintarelli</b>            TBC</p> <p>2 Oral presentations</p>	<p><b>Session 2d: AAV vector development</b>  <i>Chairs: TBC</i>  <b>Sponsor: Lonza</b></p> <p><b>INV25: Hildegard Büning</b>  <i>Hannover Medical School</i>            Title TBC</p> <p><b>INV26: Eric Kelsic</b>  <i>Harvard Medical School</i>            Title TBC</p> <p><b>INV27: David Schaffer</b>  <i>University of California, Berkeley</i>            Title TBC</p> <p>2 Oral presentations</p>
<b>Thursday 24 October 2019</b>				
8:30-10:30	<p style="text-align: center;"><b>Session 4: Stem cells &amp; clinical trials therapies</b>  <i>Chairs: TBC</i>  <b>Sponsor: Rocket</b></p> <p style="text-align: center;"><b>INV32: Juan Bueren</b>  <i>CIEMAT CIBERER, Madrid</i>            Title TBC</p> <p style="text-align: center;"><b>INV33: Michel Sadelain</b>  <i>Memorial Sloan Kettering Cancer Center, NY</i>            Title TBC</p> <p style="text-align: center;"><b>INV34: TBC</b>  <i>TBC</i>            Title TBC</p> <p style="text-align: center;"><b>INV35: TBC</b>  <i>TBC</i>            Title TBC</p>			
10:30-11:00	<b>Coffee break</b>			

11:00-13:00	<p style="text-align: center;"><b>Presidential symposium</b>  <i>Chairs: Hildegard Büning, Angel Raya</i>  <b>Sponsor: bluebird bio</b>  <b>INV30: Hildegard Büning</b>  <i>Hannover Medical School</i>            Presidential address</p> <p style="text-align: center;"><b>INV31: TBC</b>  <i>TBC</i>            Title TBC</p> <p style="text-align: center;"><b>INV32: Nathalie Cartier</b>  <b>Human Gene Therapy Outstanding achievement award</b>  <i>TBC</i>            Title TBC</p> <p style="text-align: center;"><b>Audentes Young Investigator award</b>  <i>TBC</i>            Title TBC</p>			
13:00-14:30	<b>Lunch</b> <b>Poster session II</b>			
14:30-16:30	<p><b>Session 3a: CNS gene therapy</b>  <i>Chairs: TBC</i>  <b>Sponsor: Sarepta</b></p> <p><b>INV39: Alessandra Biffi</b>  <i>Harvard Medical School, MA</i>            HSC gene therapy for neurometabolic and neurodegenerative disorders</p> <p><b>INV40: Steve Goldman</b>  <i>University of Rochester, NY</i>            Title TBC</p> <p><b>INV41: Steve Gray</b></p> <p>2 Oral presentations</p>	<p><b>Session 3b: Metabolic diseases</b>  <i>Chairs: TBC</i></p> <p><b>INV42: TBC</b>  <i>TBC</i>            Title TBC</p> <p><b>INV43: TBC</b></p> <p><b>INV44: TBC</b></p>	<p><b>Session 3c: Immune responses to gene therapy</b>  <i>Chairs: TBC</i></p> <p><b>INV45: Percy Knolle</b>  <i>TUM, Munich</i>            Mechanisms of liver tolerance and implication for liver-targeted gene therapy</p> <p><b>INV46: Roland Herzog</b>  <i>Indiana University, IN</i>            Immune response mechanisms against AAV vectors</p> <p><b>INV47: Anna Kajaste-Rudnitski</b>  <i>SR Tiget, Milan</i>            Title TBC</p>	<p><b>Session 3d: Blood diseases</b>  <i>Chairs: TBC</i></p> <p><b>INV48: Jose Carlos Segovia Sanz</b>  <i>CIEMAT CIBERER Madrid</i>            Title TBC</p> <p><b>INV49: Giuliana Ferrari</b>  <i>SR TIGET Milan</i>            Title TBC</p> <p>4 Oral presentations</p>
16:30-17:00	<b>Coffee break</b>			

17:00-19:00	<p align="center"><b>Plenary session 5: Gene editing, immune response, toxicity</b>  <i>Chairs: Giuseppe Testa, Luis Montoliu</i></p> <p align="center"><b>INV51: David Liu</b>  <i>Harvard University, MA</i>  Title TBC</p> <p align="center"><b>INV52: David Rawlings</b>  <i>University of Seattle, WA</i>  Title TBC</p> <p align="center"><b>INV53: Jim Wilson</b>  <i>University of Pennsylvania</i>  Safety and efficacy of in vivo editing in primate liver.</p> <p align="center"><b>INV53: Angelo Lombardo</b>  <i>SR Tiget</i>  Title TBC</p>			
20:00	<b>Molecular Mingle</b>			
<b>Friday 25 October 2019</b>				
09:00-10:30	<p><b>Session 4a: New approaches in gene editing</b>  <i>Chairs: TBC</i>  Sponsor: Editas</p> <p><b>INV53: Juan Rodriguez-Madoz</b>  <i>University de Navarra, Pamplona</i>  Genome editing for advanced therapies and disease models of rare metabolic diseases</p> <p><b>INV54: Claudio Mussolino</b>  <i>University of Freiburg</i>  Title TBC</p> <p>2 Oral presentations</p>	<p><b>Session 4b: Eye and ear gene therapy</b>  <i>Chairs: TBC</i>  Sponsor: Adverum</p> <p><b>INV55: Robin Ali</b>  <i>UCL, London</i>  Title TBC</p> <p><b>INV56: Luk Vandenberghe</b>  <i>Harvard Medical School, MA</i>  AAV discovery for neurosensory indications and beyond.</p> <p>2 Oral presentations</p>	<p><b>Session 4c: New delivery systems</b>  <i>Chairs: TBC</i></p> <p><b>INV57: Helmut Hanenberg</b>  <i>University of Duisburg - Essen</i>  Title TBC</p> <p><b>INV58: TBC</b></p> <p>2 Oral presentations</p>	<p><b>Session 4d: Regulatory session</b>  <i>Chairs: TBC</i></p> <p><b>INV59: TBC</b>  TBC  Title TBC</p> <p><b>INV60: TBC</b></p> <p><b>INV61: TBC</b></p> <p><b>INV62: TBC</b></p> <p>2 Oral presentations</p>
10:30-11:00	<b>Coffee break</b>			

11:00-13:00	<p><b>Session 5a: Cancer</b> <i>Chairs: TBC</i></p> <p><b>INV63: Juan Fueyo</b> <i>MD Anderson, Houston, TX</i> Virus, immunology and gliomas: new paradigms</p> <p><b>INV64: Ramon Alemany</b> <i>ICO, Barcelona</i> Title TBC</p> <p><b>INV65: Mark Kay</b> <i>TBC</i> Title TBC</p>	<p><b>Session 5b: How to make gene therapy a clinical reality?</b> <i>Chairs: TBC</i></p> <p><b>INV66: TBC</b> <i>TBC</i> Title TBC</p> <p><b>INV67: TBC</b></p> <p><b>INV68: TBC</b></p>	<p><b>Session 5c: Liver gene and cell therapy</b> <i>Chairs: TBC</i> <b>Sponsor: Intellia</b></p> <p><b>INV69: Federico Mingozi</b> <i>Spark Therapeutics, Penn</i> Title TBC</p> <p><b>INV70: Paolo Martini</b> <i>Moderna Therapeutics, MA</i> Messenger RNA therapy for Inherited Metabolic Disorders</p> <p><b>INV71: Nick Weber</b> <i>Vivet Therapeutics, Pamplona</i> Targeting the Liver to Fix the Bile: Opportunities and Challenges in Gene Therapy for Inherited Cholestasis</p> <p>2 Oral presentations</p>	<p><b>Session 5d: Late breaking</b> <i>Chairs: TBC</i></p> <p><b>INV72: TBC</b> <i>TBC</i> Title TBC</p> <p><b>INV73: TBC</b></p> <p><b>INV74: TBC</b></p>
13:00-15:00	<p><b>SETGYC General Assembly Lunch</b></p>			
15:00-16:30	<p><b>Plenary session 6: Challenges for the future</b> <i>Chairs: TBC</i></p> <p><b>INV48: Olivier Rabin</b> <i>WADA, Montreal</i> Title TBC</p> <p><b>INV49: Carl June</b> <i>University of Pennsylvania, Philadelphia</i> Title TBC</p> <p><b>INV50: Christiane Woopen</b> <i>University of Köln</i> Title TBC</p> <p><b>Keynote INV51: Kathy High</b> <i>Spark Therapeutics, Philadelphia</i> Title TBC</p> <p><b>Closing remarks</b></p>			

16:00- 17:00	<b>Closing drinks</b>
-----------------	-----------------------